56
Participants
Start Date
September 26, 2019
Primary Completion Date
December 15, 2020
Study Completion Date
June 3, 2021
Drug: GB-102
Intravitreal injection of GB-102
Aflibercept
Intravitreal injection of aflibercept (2 mg dose)
Ophthalmic Consultants of Long Island, Oceanside
Cumberland Valley Retina Consultants, Hagerstown
Mid Atlantic Retina Specialists, Hagerstown
Piedmont Eye Center, Lynchburg
Southeast Retina Center, Augusta
Specialty Retina Center, Coral Springs
Retina Specialty Institute, Pensacola
Eye Associates of Pinellas, Pinellas Park
Sterling Research, Cincinnati
Wolfe Eye Clinic - West Des Moines, Des Moines
Black Hills Regional Eye Institute, Rapid City
University Retina and Macula, Lemont
Eye Associates of Northeast Louisiana, West Monroe
Retina Specialists, Plano
Strategic Clinical Research Group LLC, Willow Park
Retina Consultants of Houston, The Woodlands
Austin Retina Associates, Austin
Retina Research Center, PLLC, Austin
Retina Research Institute of Texas, Abilene
Retinal Research Institute, Phoenix
Retinal Consultants AZ, Gilbert
Sierra Eye Associates, Reno
The Retina Partners, Encino
Retina Consultants of Orange County, Fullerton
California Retina Consultants - CRC, Santa Barbara
California Retina Research Consultants, Bakersfield
Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View
West Coast Retina Medical Group, Inc., San Francisco
Bay Area Retina Associates, Walnut Creek
Retinal Diagnostic Center of Northern California, Campbell
Retina Consultants of Hawaii, ‘Aiea
Retina Center NW PLLC, Silverdale
Florida Retina Institute, Orlando
Lead Sponsor
Graybug Vision
INDUSTRY